Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Scientific Reports|May 13, 2017
Structure and function of a broad-specificity chitin deacetylase from Aspergillus nidulans FGSC A4Zhanliang Liu, Laurie M Gay, Tina R Tuveng, et al.
Case Reports in Oncology|November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to CrizotinibJon H Chung, Siraj M Ali, Jenni Davis, et al.
Breast Cancer Research and Treatment|January 15, 2016
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling studyJeffrey S Ross, Laurie M Gay, Sahar Nozad, et al.
The American Journal of Dermatopathology|January 4, 2017
Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic MelanomaJ Andrew Carlson, Jose Candido Caldeira Xavier, Ashley Tarasen, et al.
Endocrine-Related Cancer|August 19, 2021
Targeted genomic analysis of 364 adrenocortical carcinomasNikita Pozdeyev, Lauren Fishbein, Laurie M Gay, et al.
The Oncologist|September 6, 2018
Genomic Landscape of Adult and Pediatric <i>BCR-ABL1</i>-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA SequencingEric A Severson, Jo-Anne Vergilio, Laurie M Gay, et al.
The Oncologist|March 12, 2017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> AlterationJulia A Elvin, Laurie M Gay, Rita Ort, et al.
Cancer|January 17, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3Jeffrey S Ross, Marwan Fakih, Siraj M Ali, et al.
Human Pathology|October 29, 2017
General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling studyHwajeong Lee, Tony El Jabbour, Sanaz Ainechi, et al.
Cancer|June 11, 2016
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapiesJeffrey S Ross, Laurie M Gay, Kai Wang, et al.
Pageof 4